Kantonsspital St.Gallen

Evaluation of a Candidate Vaccine Against Uropathogenic Escherichia Coli in Women With a Clinical History of Recurrent Urinary Tract Infection

Tanja Hülder & René Hornung

abstract Purpose: This Phase I multi-center placebo controlled study is conducted in healthy women with a history of recurrent urinary tract infections (UTI) aged between 18 and 70 years. GlycoVaxyn is a Swiss company that has developed a multivalent bioconjugate vaccine for the prevention of E.coli-infections. Cystitis is the most common UTI, however kidney infections or bacteremia are possible. The E. coli bacterium is responsible for 85 % of all UTIs. The objectives of this trial are to assess the safety and ability to elicit an immune response of the candidate vaccine as well as the effectiveness of the vaccine in the reduction in UTIs .
project homepage http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02...
type of project clinical studies
status completed
start of project 2014
end of project 2015
responsible person Dr. med. Tanja Hülder